

Immune Characterisation of Human local pneumotropic isolates of Streptococcus pneumoniae serotype 1 and 6 as local vaccine strains

Abstract

S. pneumoniae is one of the principle human pneumopathogen. Such pathogenicity features in man can be delineated by severity, capsule nature and yield of pure growth onto primary plate cultures. While in laboratory animal models, it accounts for; the nature of capsule serotype, shortness of time for the death end point and extent of tissue pathology. The virulent serotypes C1 and C6 of human pneumotropic *S. pneumoniae* were immune characterized as vaccine strains. Capsules were separated, identified and quantified. Then dispensed as 10mg dried amounts in ampoules. On reaching specific immune priming of rabbits the ampoules dissolved in 10 mls sterile saline and each ml admixed with 1ml lanoline and injected intramuscularly per each rabbit's thigh muscles. The immune primed rabbits left for 28 days then test bled to check for an evident immune conversion then, at the day 35 after immunization the immune rabbits were challenged with live *S. pneumoniae* 1×10^6 to six CFU/ml., in a rate of 2 mls. The carbohydrate based capsule prototype monovalent vaccines were found as; Pure, safe, antigenic, immunogenic and immune protective to the rat of 80% for C1 and 60% for C6 serotype in rabbit models. They induced systemic humoral immune precipitins responses higher than mucosal precipitin responses. Proinflammatory cytokine responses TNF alpha, TNF beta and IL6 and anti-inflammatory cytokine IL10 were mounted as mucosal responses higher than the systemic responses. The proved immune characteristics of these capsule serotypes were suggestive for use of these strain as vaccine strains along with other serotypes in development of the local prototype multiserotype vaccines of this pathogen.

Key Words

Antigenicity, cytokine, immunogenicity, immune efficacy, proinflammatory precipitins, vaccine strain

Introduction

The nature of capsule serotype in *S. pneumoniae* played as a determinantal factor in pathogenesis, pathogenicity and immunogenicity [1-10]. *S. pneumoniae* in our previous work in this area, have shown inter and intraserotype variations in pathogenicity to mice and rabbits [10]. So far the immune characterisation of the serotype 1 and 6 is concerned as a

vaccine strains[10]. There were few bacterial specific carbohydrate based vaccine that are approved for mass vaccination in human clinical practice of bacterial infectious diseases. These vaccines are available in use for those at risk human beings by the vaccine approval authorities[1]. Such as that of multiple carbohydrate based vaccine of *S.pneumoniae* [2-10]. Though at times human pneumococcal pneumonia reported every now and then at different part of the developing world countries[10]. So local human pneumotropic *S.pneumoniae* isolates gained prevalence may express different pathogenic and immunogenic potentials. Such differences may be from the same serotypes present in the current internationally approved vaccine[10,11]. The present paper aims at attempts to immune characterize human pneumotropic local serotype 1 and 6 *S.pneumoniae* isolates as local vaccine strains.

Materials And Methods

1-Seed Strains:

A collection of eight serotypes of *S.pneumoniae* that were recovered from clinical human cases of pneumonia. The study strains were elected following certain criteria both in man and laboratory animals. In man, serotype nature, severity while in animal model, serotype nature, shortness in death end point time and extent of tissue pathology. The most virulent of which were serotype 1 and 6 so they were elected for immune characterisation as vaccine strains [10].

2-Laboratory Development

The 24 hr freshly revived original isolates of each serotype 1 and 6 [author collection[10] of the *S.pneumoniae* serotype 1 and 6 growth were made onto blood agar plates. Sterile heavy swab inocula were made onto 20 trypticase soy agar plates for each serotype. The inoculated plates were incubated at 5-10% CO₂ tension at 37C for 24 hrs. Pure growth were harvested by 5 ml sterile saline solution per each plate. The suspensions were brought to PH 8.5 by the addition of 10% KOH. The alkalized suspensions were heated at 90C for 1hr in water bath. These heated suspensions let stand to cool and acidified with 5N acetic acid. The acidified suspensions then centrifuged at 5000 rpm for 10min. Pellets were discarded and supernatants were mixed with two volumes of 1% sodium acetate in 95% ethanol solution then kept at 4C for 24 hrs. Supernate and pellets were formed. The formed precipitates were removed by centrifugation at 2500rpm for 10 min. Pellets were discarded and supernatants were mixed with 5% sodium acetate in 0.5 N acetic acid for 24 hrs at 4C. These mixed solutions were centrifuged at 5000 for 30 min. Supernatant discarded and pellets were washed with 85%, 95% absolute ethanol. Then dried at 37C. The 20 plate yields 200 mg powder materials. These materials were cautiously dispensed in 10 mg per ampoule under aseptic precautions and kept till use. Each ampoule dissolved in 10 mls., sterile saline representing the immunogenic doses for 10 rabbits and stands as prototype monovalent capsular carbohydrate based experimental vaccine in rabbits[12].

3-Purity:

A purity checks were done by quadrate streak method onto trypticase soy agar plates in each step of the laboratory developmennt of the prototype monovalent pneumococcal vaccine [13].

4-Safety:

A 0.1 ml of the capsule experimental prototype vaccines were IM injected into rabbits through thigh muscles three replicates for each serotype. The injected animals were followed for up to five days. Then eviscerated to test for gross and histology changes [13].

5-Adjuvant:

Lanolin solution [13].

6-Immunogens:

One volume of lanolin was admixed with one volume of 1mg/ml. capsular polysaccharide. The mixture stands as the test immunogens [13].

7-Immunization Protocol;

The immunogen 2 ml mixture was IM injected into the thigh mscle of rabbit and left for 15 days then test bleed [13].

8-Laboratory Animals:

A group of Newzeland rabbits were acclimatzed for housing conditions for two weeks and kept ad libitum cnodition during specific immune priming and challenge experiments. These rabbits were categorized into the following groups;

Safety group.....6 Rabbits

Serotype 1 specific immune priming...10 Rabbits

Serotype 6 specific immune priming...10 Rabbits

Sham Control10 rabbits

9- Challenge Models;

The specific immune primed rabbit groups at the day 22 postpriming were challenged with live *S.pneumoniae* in strenght of 1×10^6 to six /m, survivivors were scored 21 days post challenge [14]

10- Blood Sampling:

Test and control rabbits groups were subjected to blood collection by cardiac puncture. Sera were saved , dispensed at 0.5 ml alqouts in appendroph tubes and kept at -20 till test for antibody and cytoikine levels [15]

11- Tracheal Mucosal Globulins:

Parts of the challenged and control rabbits trachea were incised and open up into sterile petri –plates . Tracheal mucosa were scrapped into the plates then 5 ml formal normal 0.5% saline were added to the scraps and mixed thoroughly and tubed into centrifuge tubes. Scraps saline tubes were centrifuge at 5000 rpm for 10 min. Supernatants were kept for processing of mucosal globulin separations in accordance with the method[16]. Pellets were discarded

12- Immune Investigations:

Determinations of antibody response levels were done by precipitation tests as in [17,18]. Cytokine response measurements were done as the manufacturer instructions.

13- Efficacy Percent Difference Statistics

Let the efficacy percent of Serotype 1 is a and Serotype 6 is b .So the Efficacy difference percentage is

$$[a-b]/[a+b/2] \times 100$$

Results;

1-Purity

All of the laboratory development purity checks onto trypticase soy agar plates were found of negative growths.

2- Safety;

Neither gross nor histologic changes were noted in the inoculated safety check rabbits.

3- Antigenicity

One from each of the vaccine lot ampoules were used for check of antigenicity test by precipitation tests.

4- Immunogenicity

4-1: Humoral Antibody Responses

The mean of serum and mucosal antibody titres for the challenged rabbits were 400 and 20 for serotype 1 and 213.33 and 13.33 for serotype 6. Systemic responses were higher than mucosal responses, Table – 1.

4-2; Cytokine Responses;

Mucosal cytokine responses were higher than systemic cytokine responses both for the serotypes 1 and 6., Table 2.

4-3; Cytokine imbalance:

Cytokine imbalance were noted in serotype 1 vaccine at mucosal response only, Table- 3.

4-4 ; Immune Efficacy :

The immune efficacy of serotype 1 was 80% and for serotype 6 was 60%, Table-4. The efficacy percentage difference is equal to 28.571%. Since practically good vaccine is that giving around 90% protection and the efficacy percentage difference approaching one third. Thus serotype C 1 is more immune protective than serotype 6 in local multivalent candidate pneumococcal vaccine taking in consideration the limits of immune interference.

4-5: Prototype Carbohydrate Based Vaccine Features

S. pneumoniae serotype 1 prototype vaccine was found; Pure, safe, antigenic, weak immunogenic needs exogenous adjuvant, induce humoral systemic precipitin responses higher than mucosal responses. Mucosal Cytokine responses were higher than systemic responses. Induce cytokine imbalance at mucosal surfaces but not at systemic compartment. It was immune efficacious to 80% in a lapin challenge model. Serotype 6 prototype vaccine was found; Pure, safe, antigenic, weak immunogenic need exogenous adjuvant. Induce systemic humoral immune responses higher than mucosal responses. Mucosal cytokine responses were higher than the systemic responses. It neither induce cytokine imbalance at mucosa nor at systemic compartment. It was immune efficacious to 60% in lapin challenge model, Table-5.

Table -1: Specific immune precipitin responses of the immune challenged rabbits.

Groups	Titres
Serotype 1 specific immune primed rabbits	
Mucosal response	20
Systemic response	400
Serotype 6 specific immune primed rabbits	
Mucosal response	13.33
Systemic response	213.33
Control rabbits	
Mucosal response	3.33
Systemic response	6.3

Table – 2 : Cytokine responses of immune primed challenged rabbits

Rabbit groups	TNF alpha	TNF beta	IL6	IL10
Serotype 1 specific immune primed challenged rabbits				
Mucosa	473.11+29	387.21 +1.39	360.59+4.3	253.36+23.5
Systemic	250+30.7	250.11+7.6	223.5+20.2	202.6 +14.5
Serotype 6 specific immune primed challenged rabbits				
Mucosa	233.55+1.4	225.25+7.3	238.8+4.9	199.68+13.5

Systemic	245.2-+35	236.32-+27.8	219.51-+59.6	200.76-+8.1
Control				
Mucosa	125.12-+55	110.35 -+11.5	93.54 -+2.5	110.25 -+ 11.5
Systemic	115.29-+11.7	101 -+11.5	100.62-+0.75	101.15 -+11.5

Table -3 ; S.pneumoniae capsular 1 and 6 primed challenged rabbits cytokine imbalance.

Rabbit groups	TNF alpha	TNF B	IL6	IL10
Serotype 1 specific immune primed challenged rabbits				
Mucosa	4:1*	3:1	3:1	2:1**
Systemic	2:1	2:1	2:1	2:1
Serotype 6 specific immune primed challenged rabbits				
Mucosa	1.5:1	2:1	2:1	2:1
systemic	1:1	1:1	2:1	1:1
Control Mucosa/systemic	1:1	1:1	1:1	1:1

- The number of folds of cytokine concentrations for the test to control rabbits

** Imbalance is the number of concentration folds for the proinflammatory to the anti-inflammatory cytokines.

Table -4 : The immune efficacy of the developed vaccines in rabbits

Prototype vaccine	Infective dose	Number of rabbits	Serve to total	Percentages
Type 1	1x10 to 6	10	8:10	80%
Type 6	1x10 to 6	10	6:10	60%
Control	1x10 to 6	10	0:10	0%

Table-5 : Features of the Carbohydrate based S.pneumoniae serotype 1 and 6 monotypic prototype vaccines in rabbit challenge model..

Features	Prototype C1	Prototype C6	Approved pneumococcal Vaccine
Understanding Disease Understanding causal	Pneumonia S.pneumoniae	Pneumonia S.pneumoniae	Pneumonia S.pneumoniae
Virulence factor	Serotype 1	Serotype 6	23 serotypes
Purity	Pure	Pure	Pure
Safety	Safe	Safe	Safe
Antigenicity	Antigenic	Antigenic	Antigenic
Immunogenicity	Immunogen*	Immunogen*	Immunogen*

Immune efficacy in rabbit	80%	60%	60%
Immune efficacy in man	?	?	

- Amplified on combination with lanlin

Discussion;

The subunit bacterins of the bacterial pathogens when introduced to the body of a small mammal laboratory animals like rabbits, Tables 1 – 5, may triggers TH1, TH2 and /or B cells to grow ,proliferate,expand and activated as an effector and/ or memory cells.As a consequences,humoral mucosal and systemic antibody responses as well as cytokine network activations both for innate and adaptive cytokine types[19,20]The systemic humoral immune responses were higher than mucosal responses[16].While the mucosal cytokine responses were higher than the systemic responses[4].Cytokine imbalance was noted betwen pro and anti-inflammatory cytokines serotype 1 at mucosal compartment but not systemic.Sertype 6 does not express imbalance at both mucosal and systemic compartments[21].The immune effcacy of the present prototype carbohydrate based capsular bacterins were ranging between 60- 80%[11,22].The vaccinologic features of the prepared candidates capsular bacterins were ;Antigenic, weak immunogenic need an exogenous adjuvant leading to antibody and cytokine responses.Such responses were both at mucosal and systemic compartments with an immune efficacy ranging between 60 to 80% in rabbit models.The proposed S.pneumoniae vaccine strains may be of help in development of an eight local pneumococcal vaccine with the other reported six serotypes[10] which may be more efficieous in this area than the internationally approved 23 pneumococcal vaccine[22].The vaccine strains form an integral part in vaccine development,since it forms the first step in vaccine development processes.S.pneumoniae serotype 1 and 6 are among the known serotypes ensembled in various up date and approve vaccine formulations[23,24].

Conclusion

Local pneumotropic isolates of *S. pneumoniae* serotype 1 and 6 were found valid as vaccine strains based on lapin immune challenged models. The proved immune characteristics of these capsule serotypes were suggestive for use of these strain as vaccine strains along with other serotypes in development of the local prototype multiserotype vaccines of this pathogen.

Competing Interest

The authors declare that they have competing interest.

Ethical Approval

Care,housing, handling and managment done on rabbits were following the international acts regulating care,housing,handling and intervensions.

DISCLAIMER(ARTIFICIAL INTELLIGENCE)

Authors hereby declare that NO generative AI technology Models (Chat GPT, COILOT, etc) and text-to-image generator have been used during writing or editing of this manuscript.

References

1-Shnawa I M S.2022.Vaccines For Biomedics:A Second Revised Edition of Vaccinology At A Glance.BPI,India-UK.

2-,Sukhova EV ,Yashunsky DV , Tsuetkov YE , Nifantiev NE .2020. High cytokine and opsonizing antibody production induced by bovine serum albumin BSA-conjugate tetrasaccharide relate to Streptococcus pneumoniae type 3 capsular polysaccharide. Front. Immunol.11:578019.doi.10.3389/fimmu/2020.578019.

3-Maddux JT , Stomberg ZR , Curtiss R III et al.2017.Evaluation of recombinant attenuated Salmonella vaccine strains for broad protection against extraintestinal pathogenic Escherichia coli.Front.Immunol. 8:1280.doi.10.3389/fimmu.2017.01-1280.

4-Kashiwagi Y , Miyata A , Kumagai T et al.2013.Production of inflammatory cytokines in response to diphtheria-pertussis DPT,hemophilic influenzae type b and 7 valent pneumococcal PCV vaccines.Vaccines and Immunotherapeutics 14(3):677-685.doi.10.4161/hv.23264.

5-dos.San, TW , Goncalves PA ,Rodriguez D et al.2022.A fusion protein comprising pneumococcal surface protein A and pneumolysin derivative confers protection in murine model of pneumococcal pneumonia.Plos.One .17(12):e0277304.doi.10.1371/journal.pone.0277304.

6-Malley R , Anderson PW. 2011.Serotype dependent pneumococcal experimental vaccine that induce cellular as well as humoral immunity.Biol.Sci.109(10):3623-3627.doi.10.1073/biolsci.112383109.

7-Turner A K 2011.Generation of a live attenuated enterotoxigenic Escherichia coli. Combination vaccine express six antigens.Clin.Vacc.Immunol.18(12):doi.1128/CVI.05345-11.

8- Kamboj K K2003.Significant variations in serotype specific immunity of seven valent S pneumoniae capsular polysaccharide CRM197 conjugate vaccine occurs despite vigorous T cell help induced by carrier protein.J.Infect.Dis.187(10):1629-1638.doi.10.1086/374785.

9-Masomian M , Ahmed Z ,Gew L Ti,Puh CL 2020.Development of next generation streptococcus pneumoniae vaccines conferring broad protection.Vaccines. 8,132;doi.10.3390/vaccines8010132.

10-AL-Janabi A A J,Shnawa IMS,ALSadi AM 2024.Inter and Intraserotype pathogenicity of Streptococcus pneumoniae in mice and rabbit.J.Pharmaceutical Research International.36(10):49-54.

11-Kayhty H , Ahan H. 2001.Bridging Phase 2 and Phase 3 pneumococcal immunogenic data for future combination vaccines Clin.Infect.Dis.33(Supl.4):S292-298.

12-Linker A , Russel S 1966.A new polysacchraide resembling alginic acid isolating. J.Clin. Chem.241(16):3845-3851.

13-Shnawa IMS.2019.Vaccine Technology At A Glance.Boffin Access.UK.

14-Yuanyi L , Marcelo G ,Miriam E.2007.Immunization with recombinant sao protein protection against Streptococcus suis infection.J.Clin. Vacc. Immunol.14(8):937-943.

15-Stevens CD.2010.Clinical Immunology and serology;A Laboratory Perspective,3rd ed.F A Davis Company.philadelphia.123-130.

16-Shnawa IMS , Thwainin QN.2002.Lapin mucosal humoral and cellular immune responses post to intratesticular administration of heat killed C.fetus bacteria.J.Bay.Sci.Appl.3 :542-558.

17-Turgeon ML.2022.Immunology And Serology in Lasboratory Medicine.7th ed.USA, Elseveirs ,48-247.

18-Lafon DC,Nahm MH 2018.Measuring Immune response to pneumococcal vaccine.J.Immunol. Methods 461:37-43.doi.10.1016/jim/2018.08.002.

19-Abbas AK , Lichtman AH,Pillali S 2015.Cellular And Molecular Immunol.8th ed.Elseveir ,Saunders Philadelphia,339-358.

20-Tiria FR,Musila L 2021.A Review of the innate evation mechanism and status of vaccine development of K.pneumoniae.Microbiol.Res.Int.31(1):33-41.

21-Bull MB , Ma FNL ,Berera L.2022.Early vaccine-mediated strain specific cytokine imbalance induces mild immunopathology during infleunza infection.Immunol. Cell.Biol .101(6):514-524.

22-Daniels CC , Shelton CM 2016. A review of pneumococcal vaccine recommendations and future protein antigen.Pediatr.Pharmacol.Ther.21(1):27-35.

23-FDA 2024,US FDA approves CAPVAXIVE TM,a pneumococcal 21 valent conjugate vaccine for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults,Merk,News Release.

24-CDC 2024.Prevnar 20 valent conjugate vaccine provides protection against pneumo -coccal disease for adults and babies .Safety Info.

